Physician profile
Rodrigo Tobar
NPI 1316014566
$5,374.33
in general payments reported to CMS, 2019-2025
21 companies · $781 in 2025
The $781 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $818 · 2020: $800 · 2021: $634 · 2022: $696 · 2023: $853 · 2024: $793 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,420 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,419.94 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,280.47 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,188.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $683.90 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $440.48 | 2019-2024 | Jardiance, Spiriva Respimat |
| Pfizer INC. | $411.60 | 2019-2025 | |
| Glaxosmithkline, LLC. | $396.91 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $360.79 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Dexcom, INC. | $142.46 | 2021-2023 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $134.31 | 2019-2022 | |
| Astellas Pharma US INC | $47.61 | 2021-2025 | Veozah |
| Esperion Therapeutics, INC. | $44.74 | 2020-2021 | |
| Shield Therapeutics INC | $38.80 | 2022 | |
| Amgen INC. | $38.40 | 2020 | |
| Sanofi-Aventis U.S. LLC | $32.25 | 2019 | |
| Amarin Pharma, INC. | $25.72 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.11 | 2025 | Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $18.65 | 2024 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $18.02 | 2023 | |
| Exact Sciences Corporation | $17.92 | 2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $17.38 | 2021 | |
| Genentech USA, INC. | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodrigo Tobar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.